Of the more than 40 genetically defined dominantly inherited hearing loss syndromes, only a few are associated with bilateral vestibulopathy. No genetic mutations have been identified in families with bilateral vestibulopathy and normal hearing. Objective: To perform a genome-wide scan for linkage in four families with dominantly inherited bilateral vestibulopathy. Methods: Patients in four families reported brief episodes of vertigo followed by imbalance and oscillopsia. Bilateral vestibulopathy was documented with quantitative rotational testing. Most patients with bilateral vestibulopathy also had migraine. A 10 cM genome-wide screen was conducted using 423 microsatellite markers to identify linkage with vestibulopathy. Results: The authors identified a 24 cM region on chromosome 6q suggestive of linkage to vestibulopathy in these four families (maximum lod score of 2.9 at marker D6S1556). A small fifth family with a different phenotype was not linked to this region on chromosome 6q. Conclusions: This is the first report of linkage in families with dominantly inherited vestibulopathy and normal hearing. Genetic heterogeneity is likely with inherited vestibulopathy.
Although mutations in many genes cause hearing loss, only a few have been associated with bilateral vestibulopathy. 1 Of the approximately 40 dominantly inherited hearing loss syndromes (DFNA), only two are associated with vestibulopathy, DFNA 9, and DFNA 11. DFNA 9 is caused by mutations in the COCH gene 2 while DFNA 11 is caused by mutations in the MYO7 gene. 3 So far, no genetic mutations have been identified in patients with familial vestibulopathy without hearing loss. The search for genetic causes of bilateral vestibulopathy has been hampered by the difficulty in identifying affected families. Unlike auditory function testing, which is readily available, quantitative vestibular function testing is available only at major medical centers. Traditional electronystagmography with caloric testing is insensitive for identifying bilateral vestibulopathy because of the wide range of normal caloric responses. Clinically, the effects of bilateral vestibulopathy are subtle compared to the effects of hearing loss because other sensory systems (particularly somatosensation and vision) help compensate for the vestibulopathy. Given the large number of genetic syndromes with hearing loss and normal vestibular function, it is reasonable to anticipate that there will be a large number of genetic syndromes with vestibulopathy and normal hearing.
In 1994, Baloh et al. 4 reported three families with a dominantly inherited bilateral vestibulopathy syndrome. Patients typically began with brief episodes of vertigo followed by a slowly progressive imbalance and oscillopsia beginning between the ages of 30 and 50. Hearing was normal in all affected patients and none had other neurologic findings. Of interest, migraine also seemed to be running in an autosomal dominant fashion with the bilateral vestibulopathy although it was unclear exactly how the migraine and the vestibulopathy were interrelated. Multiple family members without vestibulopathy had migraine symptoms. One possible interpretation is that the vestibulopathy had a much lower penetrance than other migraine symptoms. After identifying a fourth family with migraine and vestibulopathy, we performed a genome-wide scan searching for linkage. A suggestive linkage on chromosome 6q was identified and we then tested a newly reported family with bilateral vestibulopathy 5 without migraine for linkage to this region. No other families have been reported with this syndrome.
Methods.
Cases. Three of the four families were previously reported. 4 The fourth family is from Sydney, Australia, with a small branch in the United States. All four families have a similar clinical phenotype. Patients typically first noticed brief episodes of vertigo in the second or third decade followed years later by imbalance and oscillopsia. Hearing was consistently normal. Most patients with bilateral vestibulopathy also met the International Headache Society (IHS) criteria for migraine with or without aura. 6 Affected members in Families 3, 4, and 5 improved with acetazolamide 4 but this drug was not used in the other two families. No other migraine prophylactic drugs were tried. After the genome scan was completed, a small Swedish family was reported with bilateral vestibulopathy but without migraine.
The affected status was based on bilateral vestibulopathy documented with quantitative rotational testing. The gain had to be greater than 2 standard deviations below the normal mean for both sinusoidal (0.05 Hz, 120 deg/sec) and step (120 deg/sec, 140 deg/sec 2 ) changes in angular velocity. Only subjects who were tested with quantitative rotational stimuli are included in the data analysis.
Genome scan. DNA was extracted from peripheral blood of consenting members of the five families. An initial 10 cM genome wide screen of 423 microsatellite markers was conducted to identify linkage with vestibulopathy using the ABI LIMS 2.5 panel using standard methods. Genome scanning was performed using Weber Set 9 (Licor). The data from the genome-wide scan were analyzed using both a parametric and a nonparametric approach. For the parametric analysis, we assumed a dominant model with reduced penetrance (probability of disease for carriers equal to 0.5; probability of phenocopy 0.02). We assumed a disease allele frequency of 0.01, which is conservative.
The size of our Family 2 oriented our software choices; in order to be able to use data on all of the individuals available, we used Mendel version 5.0 7 for two-point parametric analysis and Simwalk 2.8.9 8, 9 for multipoint parametric and nonparametric analysis. However, the interpretation of the results of nonparametric analysis is hindered by the fact that the p values provided by Simwalk tend to be conservative and are not corrected for multiple comparisons. Furthermore, the nature of the computational strategy used in this program makes it impractical to achieve such a correction with a permutation procedure. A deterministic algorithm, like the one coded in Merlin, 10 provides exact p values and an ideal framework to obtain a correction for multiple comparisons based on resampling strategies. For this reason, we evaluated empirical genome-wide p values for the nonparametric analysis using Merlin, even if this required elimination of 13 individuals from Family 2. Indeed, in the case of nonparametric analysis, the linkage information comes exclusively from affected individuals, while unaffected individuals are used only to impute identity by descent status. For this reason, it is less "harmful" to reduce the pedigree size by dropping unaffected individuals from the analysis when using a nonparametric method. To obtain empirical genome-wide p values, we simulated 10,000 datasets with the same pedigree and genotyping structure as ours, but without linkage to vestibulopathy, and evaluated the frequency with which results supportive of linkage such as ours are obtained in these pedigrees (the procedure we followed is described in detail in Ge et al. 11 ).
Results. The two-point parametric analysis highlighted a region on chromosome 6, with the highest lod score 2.35 at marker D6S441 (table) . Multipoint analysis confirmed the relevance of this region ( figure 1A ). The lod score reached a maximum value of 2.83 in correspondence of marker D6S1556; the region that appeared linked was between markers D6S308 and D6S264, for a total of 34 cM.
We also conducted nonparametric analysis of the genome scan result. Again, the region of most significance was on chromosome 6 (figure 1B). At this stage of the investigation, we focused on chromosome 6, typing six additional microsatellite markers in the linked region.
The multipoint parametric analysis of the entire data for the region of interest on chromosome 6 is shown in figure 2 . The max lod score is 2.9, reached at marker D6S1556. The CI obtained looking at the region for which the lod score is greater than the maximum value Ϫ1 is 24 cM. The value of this lod score is not such that we can declare a genome-wide significance result based on the guidelines of Lander and Kruglyak 12 ; however, it is well above the threshold for suggestive linkage. In particular, given that the mode of inheritance may be different from what we assumed, we believe that our results represent a strong indication of linkage to the region. The nonparametric analysis using Simwalk found markers D6S144 through D6S1633 to be nominally significant; the smallest p value was 0.003 for marker D6S1556. Furthermore, based on our simulation study using Merlin, the genome-wide corrected p value for markers D6S441, D6S1556, D6S1577, and D6S1582 was 0.065. Haplotype analysis showed one haplotype harboring the disease in each family-with the caution that in Family 2 there may be two haplotypes identical to the region of interest (figure 3). We then checked the newly reported family with bilateral vestibulopathy (without migraine) and the haplotypes were not consistent with linkage to this region on chromosome 6 (see figure 3 ).
Discussion. This is the first report of linkage analysis in families with a dominantly inherited bilateral vestibulopathy syndrome associated with normal hearing. The clinical syndrome consisted of brief attacks of vertigo occurring over several years followed by the development of imbalance and head movement dependent oscillopsia characteristic of bilateral vestibular loss. The episodic vertigo typically began in the second or third decade of life whereas the symptoms of progressive vestibulopathy developed in the fourth or fifth decade. In all four families, there was a strong relationship between migraine and the symptoms of bilateral vestibular loss. Sixteen of 18 (89%) affecteds or obligate carriers met the IHS criteria for migraine. A recently reported small family with bilateral vestibulopathy that did not have migraine 5 did not link to the region on chromosome 6; thus genetic heterogeneity is likely with familial bilateral vestibulopathy. This is not surprising since there have been more than 40 distinct genetic syndromes identified for bilateral progressive hearing loss most of which have normal vestibular function. The region identified for bilateral vestibulopathy on chromosome 6 does not overlap with the chromosomal regions of any of the previously reported DFNA syndromes. The different haplotypes in the four families suggest multiple origins for the mutations causing this disorder.
It is interesting to speculate on the possible relationship between migraine and bilateral vestibulopathy in these families. Minor vestibular abnormalities (particularly unilateral loss of caloric response) are well documented in patients with migraine. 13 However, severe bilateral vestibulopathy has not been reported. Brief episodes of vertigo lasting minutes are also common with migraine, but it is unclear whether the vertigo originates from central or peripheral structures.
14 Quantitative neurotologic testing in patients with migraine has documented both peripheral and central abnormalities. 15 The abrupt onset of the short duration attacks of vertigo in these families with vestibulopathy raises the possibility of a vascular mechanism (vasospasm) but which structures are ischemic and what is the cause of ischemia remains unclear. An interesting hypothesis is that the recurrent episodes of vertigo are associated with progressive damage to vestibular structures (peripheral or central) eventually leading to bilateral vestibular loss. Since migraine is so common, however, the combination of migraine and vestibular loss in our families could be a chance occurrence or migraine may be a marker for some other genetic factor that predisposes to bilateral vestibulopathy. The bilateral vestibulopathy region on chromosome 6 does not overlap with any of the previously reported chromosomal loci linked to migraine.
The ideal candidate gene for bilateral vestibulopathy with normal hearing would be a gene expressed in the vestibular labyrinth but not in the cochlea. Unfortunately, a survey of gene expression within the vestibular labyrinth is currently not available. We are in the process of generating such a library. Opioid peptides have been identified in the inner ear and are believed to act as neurotransmitters in both the auditory and vestibular systems. A gene in the region of interest on chromosome 6, OPRM1, codes for the mu opioid receptor which recently was shown to mediate an excitatory modulatory input to afferent neurons from semicircular canals of larval axolotls. 16 However, we sequenced all of the coding regions from OPRM1 in the probands from the linked families and found no mutations. Other candidate genes in the linked region include SYNJ2, a synaptic protein, and SOD2, a mitochondrial enzyme that catalyzes the dismutation of superoxide anions. 
